TFFP: TFF Pharmaceuticals, Inc. Stock

by  •  • Comments Off on TFFP: TFF Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5.45
Enterprise Value ($M) 2.24
Book Value ($M) 5.30
Book Value / Share 1.71
Price / Book 1.03
NCAV ($M) 0.98
NCAV / Share 0.32
Price / NCAV 5.56

Profitability (mra)
Return on Invested Capital (ROIC) -3.69
Return on Assets (ROA) -1.47
Return on Equity (ROE) -1.62

Liquidity (mrq)
Quick Ratio 1.26
Current Ratio 1.26

Balance Sheet (mrq) ($M)
Current Assets 4.86
Assets 9.19
Liabilities 3.88
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.73
Operating Income -21.89
Net Income -21.24

Cash Flow Statement (mra) ($M)
Cash From Operations -16.04
Cash from Investing -0.09
Cash from Financing 5.01

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-08 13G Intracoastal Capital, Llc 4.99
05-08 13G/A Carlson Capital L P 9.12 -88.17
02-14 13G/A Lytton Laurence W 0.10 -99.62

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-07-26 3,293 9,774 33.69
2024-07-25 2,684 10,196 26.32
2024-07-24 4,414 22,780 19.38
2024-07-23 525 9,217 5.70
2024-07-22 564 22,581 2.50

(click for more detail)

Similar Companies
TCRT – Alaunos Therapeutics, Inc. TELO – Telomir Pharmaceuticals, Inc.
TENX – Tenax Therapeutics, Inc. TGTX – TG Therapeutics, Inc.
THAR – Tharimmune, Inc.


Financial data and stock pages provided by
Fintel.io